ImmunoGen, Inc.

ImmunoGen, Inc. (Nasdaq: IMGN), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.

To receive more information regarding the investigation of ImmunoGen, Inc. please fill out the form below.